Literature DB >> 19597643

Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease.

Shanmugam Saravanan1, Vijayakumar Velu, Subhadra Nandakumar, Vidya Madhavan, Uma Shanmugasundaram, Kailapuri G Murugavel, Pachamuthu Balakrishnan, Nagalingeswaran Kumarasamy, Suniti Solomon, Sadras Panchatcharam Thyagarajan.   

Abstract

BACKGROUND AND
PURPOSE: Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection accounts for a substantial proportion of liver diseases worldwide. Although the exact prevalence is not known, these viral infections are common among patients with chronic liver disease (CLD). This study was performed to determine the prevalence of HBV and HCV dual infection among patients with CLD in Chennai, India.
METHODS: 251 patients were tested for the presence of hepatitis B surface antigen (HBsAg), immunoglobulin (Ig)-M/IgG antibody to hepatitis B core antigen (anti-HBc) and anti-HCV antibodies, and HBV-DNA and HCV-RNA by qualitative polymerase chain reaction.
RESULTS: Coinfection with HCV and HBV was detected in 15 patients (5.9%), 12 of whom (80.0%) were positive for HCV-RNA and IgG anti-HBc with no evidence of HBV-DNA, while 3 HBsAg-negative patients (20.0%) were positive for HBV-DNA in addition to HCV-RNA. Liver function test profiles were significantly altered for HCV-positive patients compared with HBV-positive and HBV/HCV coinfected patients (p = 0.001). Bilirubin and alanine aminotransferase levels were significantly raised in coinfected patients compared with non-HBV, non-HCV patients (p = 0.001).
CONCLUSIONS: The results demonstrated that HBV was predominantly associated with underlying CLD among this group of patients in India and suggest that HBV coinfection in HCV-infected patients should not be excluded by negative HBsAg status alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597643

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  17 in total

Review 1.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Shiv K Sarin; Shivaram P Singh; Yogesh K Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S Puri; C E Eapen; Sandeep Thareja
Journal:  J Clin Exp Hepatol       Date:  2015-09-21

2.  Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Robert L Kruse; Jennifer R Kramer; Gia L Tyson; Zhigang Duan; Liang Chen; Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

3.  Hepatitis B & C among farmers - a seroprevalence study.

Authors:  Ravinder Garg; Shaminder Kaur; Rakesh Aseri; Simmi Aggarwal; Jatinder Pal Singh; Simarpreet Mann; Sumit Kumar; Sarabjot Kaur
Journal:  J Clin Diagn Res       Date:  2014-11-20

Review 4.  Hepatitis B virus and hepatitis C virus dual infection.

Authors:  Gaia Caccamo; Francesca Saffioti; Giovanni Raimondo
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Psychiatric Morbidity, Fatigue, Stigma and Quality of Life of Patients With Hepatitis B Infection.

Authors:  Rajesh Gupta; Ajit Avasthi; Yogesh K Chawla; Sandeep Grover
Journal:  J Clin Exp Hepatol       Date:  2020-04-13

Review 6.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Shiv K Sarin; Radha K Dhiman; Rakesh Aggarwal; Shivaram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoor; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Samir Shah; Praveen K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2014-06-24

7.  Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Gia L Tyson; Jennifer R Kramer; Zhigang Duan; Jessica A Davila; Peter A Richardson; Hashem B El-Serag
Journal:  Hepatology       Date:  2013-07-01       Impact factor: 17.425

8.  Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Masashi Ninomiya; Keiichi Tamai; Yasuhito Tanaka; Jun Inoue; Eiji Kakazu; Koju Kobayashi; Osamu Kimura; Masahito Miura; Takeshi Yamamoto; Tomoo Kobayashi; Takehiko Igarashi; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2012-05-16       Impact factor: 7.527

9.  Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report.

Authors:  Alexander R Ende; Nina H Kim; Matthew M Yeh; Jason Harper; Charles S Landis
Journal:  J Med Case Rep       Date:  2015-07-28

10.  Hepatitis B virus and hepatitis C virus co-infection in hemodialysis patients: A retrospective study from a tertiary care hospital of North India.

Authors:  Rubina Malhotra; Divya Soin; Pragati Grover; Shipra Galhotra; Himanshu Khutan; Navneet Kaur
Journal:  J Nat Sci Biol Med       Date:  2016 Jan-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.